Reumofan Plus USA, LLC & Reumofan USA, LLC is Voluntarily Recalling all lots of Reumofan Plus Tablets Due to Undeclared Drug I... ( SPRINGFIELD Pa. Feb. 15 2013 /PRN...)

HOME >> MEDICINE >> TECHNOLOGY

Reumofan Plus USA, LLC & Reumofan USA, LLC is Voluntarily Recalling all lots of Reumofan Plus Tablets Due to Undeclared Drug Ingredients

Date:2/15/2013

SPRINGFIELD, Pa., Feb. 15, 2013 /PRNewswire/ -- Reumofan Plus USA, LLC and Reumofan USA, LLC is recalling "Reumofan Plus" Tablets, Lot# 99515, exp. 09/16, because they contain undeclared active pharmaceutical ingredients: methocarbamol, dexamethasone, and diclofenac. Use of this product could result in serious and life-threatening injuries.

Reumofan Plus is used as a treatment for muscle pain, arthritis, osteoporosis, bone cancer and other conditions. This product comes in thirty (30) tablet containers and is packaged in a green and gold box. Reumofan Plus was distributed nationwide through internet sales.

One illness has been reported to date in connection with this problem.

The recall was initiated after it was discovered that the product was distributed in packaging that did not reveal the presence of the active pharmaceutical ingredients, making it an unapproved drug.

Distribution of the product has been completely terminated by Reumofan Plus USA, LLC and Reumofan USA.

Consumers that have Reumofan Plus should be aware that the product may pose a serious health risk. Consumers who are taking these products or who have recently stopped taking Reumofan Plus should immediately consult a health care professional. Consumers who have purchased the thirty (30) tablet containers of Reumofan Plus are urged to return them, to; Reumofan Plus USA, LLC & Reumofan USA, LLC, 737 Buttonwood Drive, Springfield, PA 19064, where they will be exchanged for a new all-natural supplement of herbs only. This product was independently lab-tested to contain only all-natural herbs.

Consumers with questions may contact the company at (610) 544-9761, Monday thru Friday, between 10:00 a.m. and 2:00 p.m. EST.
'/>"/>

SOURCE Reumofan USA, LLC
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
3. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
4. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
8. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
9. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
10. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism

Post Your Comments:

(Date:5/22/2013)... NEW YORK , May 22, 2013 Ohr ... the development of novel therapeutics for unmet medical needs, ... Almenoff , M.D., Ph.D., to its Board of ... industry, working on early and late stage drug development. ... Almenoff join Ohr,s Board," said Dr. Irach Taraporewala, CEO ...

(Date:5/22/2013)... May 22, 2013 Varian Medical Systems ... received 510(k) clearance from the U.S. Food and ... processing workstation that combines radio frequency (RF) and ... Nexus DRF Digital X-Ray Imaging System™ has the ... receptors, including CCD cameras and commercially available flat-panel ...

(Date:5/22/2013)... Ambit Biosciences Corporation (Nasdaq: AMBI ... quizartinib (AC220), a potent and selective FLT3 inhibitor, will ... Society of Clinical Oncology, held May 31 through June ... . Information about the abstracts, ... can be viewed online at http://abstracts2.asco.org/ . Abstract ...

Breaking Medicine Technology:Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 2 Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 3 Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System 2 Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology 2 Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology 3

[0] Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors [0] Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System [0] Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology

... Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - ... develops new uses for previously approved drugs and new molecular ... Cast on Thursday, January 26, 2012 at 4:15 EST. The ... on the company,s progress and a press release on January ...

... DIEGO, Jan. 5, 2012 Verenium Corporation (Nasdaq: ... on the development and commercialization of high-performance enzymes, today ... for the removal of filter cake in drilling operations. ... acts as a barrier to hydrocarbon flow on the ...

Cached Medicine Technology:Ampio Pharmaceuticals Schedules Webcast to Update Shareholders 2 Ampio Pharmaceuticals Schedules Webcast to Update Shareholders 3 Verenium Launches Second Enzyme Product for Oilfield Services 2 Verenium Launches Second Enzyme Product for Oilfield Services 3

Ampio Pharmaceuticals Schedules Webcast to Update Shareholders Verenium Launches Second Enzyme Product for Oilfield Services

(Date:5/22/2013)... Ore. A new study shows there is a ... in American young children one that does not ... the United States, girls had higher levels of self-regulation ... control their behavior and impulses, follow directions, and persist ... performance and college completion, in past studies by Oregon ...

(Date:5/22/2013)... 2013 DePuy Pinnacle lawsuit ... Hip Replacement System continue to move forward in the ... LLP reports. According to an Order dated May ... monitoring reports associated with a 2007 criminal investigation by ... practices. Plaintiffs maintained in their December 2012 ...

(Date:5/22/2013)... Twenty student-led startup companies at Arizona ... an intensive startup accelerator designed to help them execute ... create local jobs as part of ASU’s Edson ... initiative offers approximately 20 student teams up to $20,000 ... to launch their for-profit, more-than-profit or nonprofit ventures. The ...

(Date:5/22/2013)... Over the next two decades, the cost of treating ... than double, topping more than $180 billion a year, ... the increase: an aging population. The report, from the ... was published May 22 in the journal Stroke ... system," Dr. Bruce Ovbiagele, chairman of the department of ...

(Date:5/22/2013)... Sleepy Hollow, New York (PRWEB) May 22, 2013 ... New York, has established the Westchester Lung Nodule Center ... lung nodules or receive lung cancer care. Lung cancer is ... Each year, more people in the U.S. die from ... , As with all cancers, early detection increases survival ...

[0] 'Boys will be boys' in US, but not in Asia [0] DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation [0] ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort [0] Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report [0] Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care

... 17 Fleishman-Hillard Inc. today pledged,$250,000 in global ... fight to reduce micronutrient deficiencies in developing countries.,Adopting ... Food and,Agribusiness Practice will provide communications strategy and ... of flour standard,practice around the world., One-third ...

... the country has found that protocols followed to determine brain ... 22 issue of the journal Neurology, a team of researchers ... top neurology and neurosurgery centers by U.S. News and World ... American Academy of Neurology (AAN). The paper has received ...

... VIEW, Calif., Jan. 17 ChemoCentryx, Inc. today,announced ... the company,s,Board of Directors. Dr. Penhoet is recognized ... the public and private sectors of the life,sciences ... of,Chiron Corporation (now Novartis)., Dr. Penhoet is ...

... Nationwide Campaign Challenging U.S. to Close the Gaps in ... Breast Cancer Care, ... the,Ohio Affiliates of Susan G. Komen for the Cure will host ... nationwide,tour to close the gaps in breast cancer care that cause ...

... hunt for human viruses described in this weeks issue ... found the cause of Kaposis sarcoma has revealed a ... deadly skin cancer called Merkel cell carcinoma. In the ... Feng, Ph.D., Masahiro Shuda, Ph.D., Yuan Chang, M.D., and ...

... Decision on kids aged 2-12 expected this spring, officials add ... Food and Drug Administration on Thursday issued a public health ... be given to infants and children under the age of ... when used in the very young has been widely aired ...

Cached Medicine News:Health News:Fleishman-Hillard Names FFI Global Cause for 2008 2 Health News:Study finds significant differences in protocols hospitals use to determine brain death 2 Health News:ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors 2 Health News:ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors 3 Health News:Susan G. Komen for the Cure, U.S. Congressman Pat Tiberi, Ohio Senator Tom Niehaus, and OhioHealth Riverside Breast Health Center Call for Action on Breast Cancer 2 Health News:Newly discovered virus linked to deadly skin cancer 2 Health News:Newly discovered virus linked to deadly skin cancer 3 Health News:Newly discovered virus linked to deadly skin cancer 4 Health News:Cold Meds Not Safe for Kids Under 2, FDA Warns 2 Health News:Cold Meds Not Safe for Kids Under 2, FDA Warns 3 Health News:Cold Meds Not Safe for Kids Under 2, FDA Warns 4

Fleishman-Hillard Names FFI Global Cause for 2008 Study finds significant differences in protocols hospitals use to determine brain death ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors Susan G. Komen for the Cure, U.S. Congressman Pat Tiberi, Ohio Senator Tom Niehaus, and OhioHealth Riverside Breast Health Center Call for Action on Breast Cancer Newly discovered virus linked to deadly skin cancer Cold Meds Not Safe for Kids Under 2, FDA Warns

... Sports Medicine™ POLYSORB™ Soft Tissue Anchor 3 mm ... soft tissue to bone using sutures. The resorbable ... in the bone, and is used to attach ... a resorbable copolymer, derived from glycolide and lactide ...

... USS Sports Medicine™ POLYSORB™ Soft Tissue Anchor 2 ... attach soft tissue to bone using sutures. The ... hole in the bone, and is used to ... made of a resorbable copolymer, derived from glycolide ...

Sutureless Harpoon Tip...

... type of anchor is generally utilized when a ... into the bone. Unlike other anchors that require ... does not have that limitation. The only instrument ... a mallet. The 4.4mm Stainless Steel Anchor is ...

Medicine Products:

POLYSORB™ Soft Tissue Reattachment System, 3mm POLYSORB™ Soft Tissue Reattachment System, 2mm Sutureless Harpoon Tip Collared Harpoon® Anchor